Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Informed Consent in Randomized Quality Improvement Trials

Informed Consent in Randomized Quality Improvement Trials Opinion EDITORIAL Informed Consent in Randomized Quality Improvement Trials A Critical Barrier for Learning Health Systems Mark J. Pletcher, MD, MPH; Bernard Lo, MD; Deborah Grady, MD The widespread implementation of electronic medical rec- not complete the end-of-trial survey (a departure from “in- ords (EMRs), stimulated by the Patient Protection and Afford- tention-to-treat” principles and an invitation to selection bias); able Care Act, provides a major opportunity to conduct (2) the contact and informed consent statement may have al- inexpensive pragmatic ran- tered participants’ behavior or how they report that behavior 1,2 domized trials that are em- (perhaps differentially so between treatment arms); and (3) the bedded into the clinical prac- surveys dramatically increased the burden on both partici- Related article page 671 tice of health care delivery. pants (time) and investigators (expense). This last problem se- Electronic medical records allow health systems to identify par- verely limits the scalability of the trial design: If the adminis- ticular types of patients, deliver targeted interventions de- trative costs and burdens of a study, excluding the cost of the signed to improve health, and measure how those interven- QI intervention itself, must increase directly with the sample tions impact health care http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Informed Consent in Randomized Quality Improvement Trials

Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/informed-consent-in-randomized-quality-improvement-trials-YgiQfQ56YL
Publisher
American Medical Association
Copyright
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2013.13297
pmid
24615554
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Informed Consent in Randomized Quality Improvement Trials A Critical Barrier for Learning Health Systems Mark J. Pletcher, MD, MPH; Bernard Lo, MD; Deborah Grady, MD The widespread implementation of electronic medical rec- not complete the end-of-trial survey (a departure from “in- ords (EMRs), stimulated by the Patient Protection and Afford- tention-to-treat” principles and an invitation to selection bias); able Care Act, provides a major opportunity to conduct (2) the contact and informed consent statement may have al- inexpensive pragmatic ran- tered participants’ behavior or how they report that behavior 1,2 domized trials that are em- (perhaps differentially so between treatment arms); and (3) the bedded into the clinical prac- surveys dramatically increased the burden on both partici- Related article page 671 tice of health care delivery. pants (time) and investigators (expense). This last problem se- Electronic medical records allow health systems to identify par- verely limits the scalability of the trial design: If the adminis- ticular types of patients, deliver targeted interventions de- trative costs and burdens of a study, excluding the cost of the signed to improve health, and measure how those interven- QI intervention itself, must increase directly with the sample tions impact health care

Journal

JAMA Internal Medicine – American Medical Association

Published: May 1, 2014

References

  • A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.
    Thorpe, KE; Zwarenstein, M; Oxman, AD
  • Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.
    Tunis, SR; Stryer, DB; Clancy, CM
  • Proactive tobacco treatment and population-level cessation: a pragmatic randomized clinical trial [published online March 10, 2014].
    Fu, SS; van Ryn, M; Sherman, SE
  • Ethics and informed consent for comparative effectiveness research with prospective electronic clinical data.
    Faden, R; Kass, N; Whicher, D; Stewart, W; Tunis, S
  • Pragmatic randomised trials using routine electronic health records: putting them to the test.
    Staa, TP; Goldacre, B; Gulliford, M
  • Is informed consent always necessary for randomized, controlled trials?
    Truog, RD; Robinson, W; Randolph, A; Morris, A
  • Combined pharmacotherapy and behavioural interventions for smoking cessation.
    Stead, LF; Lancaster, T
  • The tension between needing to improve care and knowing how to do it.
    Auerbach, AD; Landefeld, CS; Shojania, KG
  • Determining when quality improvement initiatives should be considered research: proposed criteria and potential implications.
    Casarett, D; Karlawish, JH; Sugarman, J
  • Oversight of quality improvement: focusing on benefits and risks.
    Lo, B; Groman, M